Fong Clinical Risk Score for Colorectal Cancer Recurrence
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Score 00–0
- Score 11–1
- Score 22–2
- Score 33–3
The Fong Clinical Risk Score for Colorectal Cancer Recurrence calculator is designed for bedside predicting recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic regimens, planning.
Clinical Guidelines & Evidence
Predicts recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection. Developed from analysis of 1,001 consecutive cases to identify high-risk patients who may benefit from adjuvant therapy or closer surveillance.
Clinical Indication
The Fong Clinical Risk Score for Colorectal Cancer Recurrence is indicated for bedside clinical practice to support Predicts recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection. Developed from analysis of 1,001 consecutive cases to identify high-risk patients who may benefit from adjuvant therapy or closer surveillance.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Not intended to exclude patients from surgery but to stratify risk and guide treatment decisions.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Not intended to exclude patients from surgery but to stratify risk and guide treatment decisions.
Sum of points: Node-positive primary (1 point) + Disease-free interval <12 months (1 point) + Multiple tumors (1 point) + CEA >200 ng/mL (1 point) + Largest tumor >5 cm (1 point)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| node_positive_primary | string | Yes | Node-positive primary tumor (lymph node involvement at primary site) |
| disease_free_interval | string | Yes | Disease-free interval from primary tumor resection to liver metastasis detection |
| number_of_tumors | string | Yes | Number of liver metastases |
| cea_level | string | Yes | Preoperative carcinoembryonic antigen (CEA) level(ng/mL) |
| largest_tumor_size | string | Yes | Size of largest liver metastasis(cm) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Score 0 | Excellent prognosis |
| 1–1 | Score 1 | Good prognosis |
| 2–2 | Score 2 | Moderate prognosis |
| 3–3 | Score 3 | Poor prognosis |
| 4–4 | Score 4 | Very poor prognosis |
| 5–5 | Score 5 | Extremely poor prognosis |
Evidence-Based References (EBM)
- Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-318.
- Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26(11):1348-1353.
- Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg. 2004;139(11):1168-1172.
- Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77(7):1254-1262.